NEW YORK, Oct. 2, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Lantheus Holdings, Inc. (NASDAQ: LNTH). Stockholders will receive 0.2502 shares of Lantheus Holdings common stock for each share of Progenics Pharmaceuticals stock that they hold. The transaction is valued at approximately $412 million and is expected to close in the first quarter of 2020.
If you are a stockholder of Progenics Pharmaceuticals, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/pgnx. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at email@example.com, or by telephone at 914-400-1920 or 844-400-4643 (toll-free).
Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com.
Attorney Advertising. Prior results do not guarantee a similar outcome.
SOURCE Rowley Law PLLC